Zobrazeno 1 - 10
of 100
pro vyhledávání: '"Valentina Burgio"'
Autor:
Margherita Rimini, Carles Fabregat-Franco, Valentina Burgio, Sara Lonardi, Monica Niger, Mario Scartozzi, Ilario Giovanni Rapposelli, Giuseppe Aprile, Francesca Ratti, Federica Pedica, Helena Verdaguer, Mario Rizzato, Federico Nichetti, Eleonora Lai, Alessandro Cappetta, Teresa Macarulla, Matteo Fassan, Filippo De Braud, Andrea Pretta, Francesca Simionato, Francesco De Cobelli, Luca Aldrighetti, Lorenzo Fornaro, Stefano Cascinu, Andrea Casadei-Gardini
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-12 (2022)
Abstract IDH1-mutated cholangiocarcinomas (CCAs) are an interesting group of neoplasia with particular behavior and therapeutic implications. The aim of the present work is to highlight the differences characterizing IDH1m and IDH1wt CCAs in terms of
Externí odkaz:
https://doaj.org/article/49008ad5b7a4484585f1c9926745098f
Autor:
Margherita Rimini, Valentina Burgio, Lorenzo Antonuzzo, Lorenza Rimassa, Ester Oneda, Caterina Soldà, Pasqua Cito, Guglielmo Nasti, Daniele Lavacchi, Valentina Zanuso, Mario Domenico Rizzato, Alberto Zaniboni, Alessandro Ottaiano, Mara Persano, Noemi Cornara, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: The results of the phase III ClarIDHy trial led to the FDA approval of ivosidenib as a therapeutic option for patients with locally advanced or metastatic cholangiocarcinoma (CCA) harboring isocitrate dehydrogenase 1 (IDH1) mutations. We
Externí odkaz:
https://doaj.org/article/69f677a554184995a75623a191483dc2
Autor:
Andrea Casadei-Gardini, Margherita Rimini, Masatoshi Kudo, Shigeo Shimose, Toshifumi Tada, Goki Suda, Myung Ji Goh, Andre Jefremow, Mario Scartozzi, Giuseppe Cabibbo, Claudia Campani, Emiliano Tamburini, Francesco Tovoli, Kazuomi Ueshima, Tomoko Aoki, Hideki Iwamoto, Takuji Torimura, Takashi Kumada, Atsushi Hiraoka, Masanori Atsukawa, Ei Itobayashi, Hidenori Toyoda, Naoya Sakamoto, Takuya Sho, Wonseok Kang, Jürgen Siebler, Markus Friedrich Neurath, Valentina Burgio, Stefano Cascinu
Publikováno v:
Liver Cancer (2022)
Introduction: In the REFLECT trial, lenvatinib was found to be non-inferior compared to sorafenib in terms of Overall Survival. Here, we analyze the effects of lenvatinib in the real-life experience of several centers across the world, and to identif
Externí odkaz:
https://doaj.org/article/08c68969bf5f4251a200dc0cdcbbbea5
Autor:
Margherita Rimini, Mara Persano, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Fabio Piscaglia, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Margarida Montes, Caterina Vivaldi, Caterina Soldà, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Lorenza Rimassa, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini
Publikováno v:
Targeted Oncology. 18:221-233
Autor:
Margherita Rimini, Carles Fabregat-Franco, Mara Persano, Valentina Burgio, Francesca Bergamo, Monica Niger, Mario Scartozzi, Ilario Giovanni Rapposelli, Giuseppe Aprile, Francesca Ratti, Federica Pedica, Helena Verdaguer, Mario Rizzato, Federico Nichetti, Eleonora Lai, Alessandro Cappetta, Teresa Macarulla, Matteo Fassan, Filippo De Braud, Andrea Pretta, Francesca Simionato, Francesco De Cobelli, Luca Aldrighetti, Lorenzo Fornaro, Stefano Cascinu, Andrea Casadei-Gardini
Publikováno v:
Targeted Oncology. 18:139-145
Autor:
Margherita Rimini, Eleonora Loi, Carles Fabregat-Franco, Valentina Burgio, Sara Lonardi, Monica Niger, Mario Scartozzi, Ilario G. Raposelli, Giuseppe Aprile, Francesca Ratti, Federica Pedica, Helena Verdaguer, Mario Rizzato, Federico Nichetti, Eleonora Lai, Alessandro Cappetta, Teresa Macarulla, Matteo Fassan, Filippo De Braud, Andrea Pretta, Francesca Simionato, Francesco De Cobelli, Luca Aldrighetti, Lorenzo Fornaro, Stefano Cascinu, Patrizia Zavattari, Andrea Casadei-Gardini
Publikováno v:
European Journal of Cancer. 175:299-310
IDH1-mutated intrahepatic cholangiocarcinomas (IDH1m iCCAs) could be treated with anti-IDH1 drugs, although the high heterogeneity in this class of tumours could limit treatment efficacy.We selected 125 IDH1m iCCAs that were treated as resectable, lo
Autor:
Angelo Della Corte, Claudio Sallemi, Francesca Ratti, Lorenzo Monfardini, Simone Gusmini, Federica Cipriani, Renato Pennella, Domenico Santangelo, Valentina Burgio, Andrea Casadei-Gardini, Luca Aldrighetti, Francesco De Cobelli
Publikováno v:
CardioVascular and Interventional Radiology. 46:49-59
Neutrophil-to-lymphocyte ratio (NLR) recently demonstrated predictive value for hepatocellular carcinoma (HCC) recurrence after thermal ablation. Microwave ablation (MWA) has been shown to induce changes in the immune landscape after HCC treatment. T
Autor:
Margherita Rimini, Valentina Burgio, Lorenzo Antonuzzo, Lorenza Rimassa, Ester Oneda, Daniele Lavacchi, Nicola Personeni, Francesca Ratti, Federica Pedica, Angelo Della Corte, Mara Persano, Francesco De Cobelli, Luca Aldrighetti, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini
Publikováno v:
Targeted Oncology. 17:591-596
The results of the phase III ClarIDHy trial have led to US FDA approval of ivosidenib as a therapeutic option for patients with locally advanced or metastatic cholangiocarcinoma (CCA) harboring isocitrate dehydrogenase 1 (IDH1) mutations.In this stud
Autor:
Valentina Burgio, Massimo Iavarone, Giovan Giuseppe Di Costanzo, Fabio Marra, Sara Lonardi, Emiliano Tamburini, Fabio Piscaglia, Gianluca Masi, Ciro Celsa, Francesco Giuseppe Foschi, Marianna Silletta, Daniela Caterina Amoruso, Margherita Rimini, Mariangela Bruccoleri, Raffaella Tortora, Claudia Campani, Caterina Soldà, Massimo Giuseppe Viola, Antonella Forgione, Fabio Conti, Francesca Salani, Silvia Catanese, Carmelo Marco Giacchetto, Claudia Angela Maria Fulgenzi, Carmine Coppola, Pietro Lampertico, Antonio Pellino, Gabriele Rancatore, Giuseppe Cabibbo, Francesca Ratti, Federica Pedica, Angelo Della Corte, Massimo Colombo, Francesco De Cobelli, Luca Aldrighetti, Stefano Cascinu, Andrea Casadei-Gardini
Publikováno v:
Cancer Management and Research, Vol Volume 13, Pp 9379-9389 (2021)
Cancer Management and Research
Cancer Management and Research
Valentina Burgio,1 Massimo Iavarone,2 Giovanni Giuseppe Di Costanzo,3 Fabio Marra,4 Sara Lonardi,5,6 Emiliano Tamburini,7 Fabio Piscaglia,8 Gianluca Masi,9,10 Ciro Celsa,11 Francesco Giuseppe Foschi,12 Marianna Silletta,13 Daniela Caterina Amoruso,14
Autor:
Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Lorenza Rimassa, José Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Takumi Kawaguchi, Margarida Montes, Caterina Vivaldi, Caterina Soldà, Fabio Piscaglia, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Massimo Iavarone, Giovanni Di Costanzo, Fabio Marra, Mario Scartozzi, Emiliano Tamburini, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Antonella Cammarota, Valentina Burgio, Stefano Cascinu, Andrea Casadei-Gardini
Purpose: The purpose of this study is to compare response rates of lenvatinib and atezolizumab plus bevacizumab, in first-line real-world setting. Methods: Overall cohort included Western and Eastern hepatocellular carcinoma (HCC) patient populations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c44a7f9afd3ac1d109f57a5526a43ce
https://hdl.handle.net/10447/583022
https://hdl.handle.net/10447/583022